Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 12:00PM GMT
Release Date Price: $152.92 (+0.74%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Great. My name is Gena Wang. I'm SMID-cap biotech analyst at the Barclays. Welcome to our first in-person Global Healthcare Conference post pandemic. I hope pandemic is ending. It's really nice to see everyone in person and I would like to also thank all the participants, investors, companies and especially our event team and the corporate access team who made this event possible.

With that, I would like to introduce our first presenting company, Alnylam. Jeff Poulton, Chief Financial Officer, will be with us today. Thank you very much, Jeff.

Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP

Thank you. Nice to be here.

Huidong Wang;Jeffrey V. Poulton
Barclays Bank PLC, Research Division - Research Analyst;Alnylam

Yes. So before I start with any questions, do you want to just highlight very high-level overview of Alnylam, how much has been achieved in the past several decades now?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot